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Abstract
Target selective drugs, such as dopamine receptor (DR) subtype selective ligands, are developed for enhanced therapeutics
and reduced side effects. In silico methods have been explored for searching DR selective ligands, but encountered
difficulties associated with high subtype similarity and ligand structural diversity. Machine learning methods have shown
promising potential in searching target selective compounds. Their target selective capability can be further enhanced. In
this work, we introduced a new two-step support vector machines target-binding and selectivity screening method for
searching DR subtype-selective ligands, which was tested together with three previously-used machine learning methods
for searching D1, D2, D3 and D4 selective ligands. It correctly identified 50.6%–88.0% of the 21–408 subtype selective and
71.7%–81.0% of the 39–147 multi-subtype ligands. Its subtype selective ligand identification rates are significantly better
than, and its multi-subtype ligand identification rates are comparable to the best rates of the previously used methods. Our
method produced low false-hit rates in screening 13.56 M PubChem, 168,016 MDDR and 657,736 ChEMBLdb compounds.
Molecular features important for subtype selectivity were extracted by using the recursive feature elimination feature
selection method. These features are consistent with literature-reported features. Our method showed similar performance
in searching estrogen receptor subtype selective ligands. Our study demonstrated the usefulness of the two-step target
binding and selectivity screening method in searching subtype selective ligands from large compound libraries.
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Introduction
Drugs that selectively modulate protein subtypes are highly
useful for achieving therapeutic efficacies at reduced side effects
[1,2,3,4]. For some targets such as dopamine receptors, all of the
approved drugs are subtype non-selective, and this non-selectivity
directly contributes to their observed side effects and adversely
affects their application potential [4]. There is a need for
developing subtype selective drugs against these targets [3,4,5,6,7].
The drug-binding domains of some protein subtypes are highly
similar to each other. For instance, the sequence similarities
among the transmembrane regions of dopamine receptor subtypes
are at high levels of 72%, 73% and 90% between D2-like
subfamily members D2 and D4, D3 and D4, and D2 and D3
respectively [8], and at the levels of 68%, 70% and 66% between
D1 and D2, D1 and D3 and D1 and D4 respectively. Ligand
binding selectivity to these subtypes is both determined by the
structural and physicochemical features of the conserved and non-
conserved residues [9]. For instance, while D2 receptor and D3
receptor share high sequence identity in the seven helices regions
that make up most of the binding sites, different compositions of
the loop regions affect the contour and topography of the binding
pockets and hydrogen bonding sites, which enables subtype
selective binding [10,11]. On the other hand, D2/D4 selectivity
has been suggested to be determined by mutated residues within
the second, third, and seventh membrane-spanning segments [9].
The high sequence similarity levels make it more difficult to
develop dopamine receptor subtype-selective drugs. Efforts have
been made in exploring in-silico methods for searching dopamine
receptor subtype-selective drug leads against highly similar
subtypes. For instance, 3D-QSAR models have been developed
for D2, D3 and D4 selective ligands respectively, achieving good
prediction performances with R
2 and Q
2 values in the ranges of
0.89–0.97 and 0.58–0.84 respectively [10,11,12,13]. A GALA-
HAD based selective pharmacophore model has been constructed
for D1/D2 selective agents [14]. CoMFA and CoMSIA models
have been developed for D2, D3 and D4 selective ligands [15].
These models have been developed by using 12–163 ligands.
Significantly higher numbers of dopamine receptor ligands
including subtype selective [2,4] and multi-subtype [16,17] ligands
have been reported. These ligands are of high structural diversity.
The published D1, D2, D3 and D4 ligands are distributed in 225,
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90–388 families covered by the inhibitors of many kinases [18].
These structurally diverse ligands are not expected to be fully
presented by the existing models trained from limited numbers of
ligands. More extensive exploration of the available ligands is
needed for developing more effective in-silico tools for searching
subtype-selective dopamine receptor ligands.
Machine learning methods are particularly useful for developing
virtual screening (VS) models from structurally diverse compounds
and for searching large chemical libraries [19,20,21]. The
purchasable real chemical libraries have been expanded to
.1 million compounds [22] and the public chemical databases
have been expanded at faster paces with PubChem [23], ZINC
[24], and ChEMBL [25] databases accumulating .30 million
compounds, .13 million purchasable compounds, and .1 mil-
lion bioactive compounds respectively. The available chemical
space defined by these databases may be more extensively
explored by the use of machine learning methods [26,27].
Moreover, several multi-label machine learning methods have
been used for developing in-silico tools to predict protein selective
compounds within a protein family or subfamily. For instance,
multi-label support vector machines (ML-SVM), multi-label k-
nearest-neighbor (ML-kNN) and multi-label counter-propagation
neural network (ML-CPNN) methods have been used for
predicting isoform specificity of P450 substrates [28,29]. Combi-
natorial support vector machines (Combi-SVM) method has been
used for identifying dual kinase inhibitors selective against single
kinase inhibitors of the same kinase pair and inhibitors of other
kinases [18]. It is of interest to explore some of these methods and
to evaluate their capability in predicting subtype selective
dopamine receptor ligands.
These existing methods are based on statistical learning
algorithms trained by compounds active and inactive against a
specific protein or subtype [18,19,28,29]. In these algorithms, the
inactive chemical space can be represented by a large number of
inactive compounds in a training dataset that typically include
representative compounds of chemical families or biological
classes. In particular the inactive training dataset of a subtype is
typically too large to further add sufficient number of active
compounds of other subtypes [18,19,28,29]. Consequently,
although these methods have shown good performance in selecting
ligands of a subtype, they do not always distinguish subtype
selective and non-selective ligands at good accuracy levels. For
instance, the ML-SVM, ML-kNN and ML-CPNN methods
predict 34%–89% isoform selective substrates as selective and
82%–99% isoform non-selective substrates as non-selective [28].
Combi-SVM identifies 51.9%–96.3% single kinase inhibitors as
kinase selective with respect to a specific kinase pair and 12.2%–
57.3% dual kinase inhibitors as dual inhibitors [18]. Therefore,
new methods need to be explored for better distinguishing subtype
selective and non-selective ligands.
In this work, we introduced a new method, the two-step binary
relevance SVM (2SBR-SVM) method for improving the ability in
distinguishing subtype selective and non-selective ligands. Our
method adopts a two-step approach, with the first step focusing on
the identification of putative ligands of a receptor subtype
regardless of their possible binding to other subtypes, and the
second step focusing on the further separation of subtype selective
and multi-subtype ligands. In the first step, a SVM model was
developed for each receptor subtype to select putative ligands
regardless of their possible binding to other subtypes using the
same method as that described in our earlier studies [19]. In the
second step, the Binary relevance (BR) method [30] was used for
more refined separation of subtype selective and multi-subtype
ligands. Specifically, the training datasets of the multiple receptor
subtypes were re-arranged into multiple new training datasets, one
for each subtype. For a particular subtype, the ligands of that
subtype were used as positive samples and the ligands of the other
subtypes as the negative samples to train a SVM model for
maximally separating ligands of a subtype with those of other
subtypes.
Our new method 2SBR-SVM was tested together with three
previously-used methods Combi-SVM [18] and two methods in
the Mulan software package [30]: the ML-kNN [28,31] and
Random k-labelset Decision Tree (RAkEL-DT) [32,33] methods.
The purpose of these tests was to evaluate the performance of the
previously used methods, and to determine to what extent our new
method can improve the performance in selecting dopamine
subtype selective ligands.
A number of dopamine receptor subtype selective ligands have
been therapeutically explored. For instance, most currently used
dopamine agonists for the symptomatic treatment of Parkinson’s
disease are selective for D2-like receptors primarily because drugs
acting on both the D1 and D2 receptor families tend to additively
Table 1. Datasets of our collected dopamine receptor D1, D2, D3 and D4 ligands, non-ligands and putative non-ligands.
Training Dataset Independent Testing Dataset
Dopamine Receptor
Subtype
Positive
Samples
Negative
Samples
Positive
Samples
Negative
Samples
Ligands published
before 2010 (No of
chemical families
covered by
ligands)
Non-ligands
published before
2010
Putative
non-ligands
Ligands published since
2010
(percent of ligands
outside training
chemical families)
Non-ligands published since
2010
D1 491 (225) 264 65198 59 (25.42%) 25
D2 2202 (642) 1577 63687 135 (16.30%) 65
D3 1355 (463) 631 62927 76 (18.42%) 28
D4 1486 (433) 526 63272 29 (34.48%) 33
Dopamine receptor D1, D2, D3 and D4 ligands (Ki ,1 mM) and non-ligands (ki .10 mM) were collected as described in method section, and putative non-ligands were
generated from representative compounds of compound families with no known ligand. These datasets were used for training and testing the multi-label machine
learning models.
doi:10.1371/journal.pone.0039076.t001
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drugs have exhibited therapeutic efficacy in animal studies [35]
and clinical trials [36]. D3-selective drugs have been explored for
the treatment of schizophrenia and drug addiction [37,38]. D4-
selective ligands have shown therapeutic potential against erectile
dysfunction [39,40]. Efforts have also been directed to the
development of D1-selective [41,42] ligands against Parkinson’s
disease and other related CNS disorders. Therefore, our tests were
conducted on D1, D2, D3 and D4 selective and non-selective
ligands.
Our VS models were trained from 491–2202 dopamine
receptor D1, D2, D3, and D4 ligands published before 2010 with
all the known subtype selective ligands and some known multi-
subtype ligands excluded. The reason for the exclusion of these
subtype selective and multi-subtype ligands from the training
process is to test to what extent our VS models can identify
subtype selective ligands without explicit knowledge of the known
subtype selective and multi-subtype ligands. The prediction
performance of these models was evaluated by 29–135 known
D1, D2, D3 and D4 ligands and 25–65 known non-ligands
published since 2010 and not in the training datasets. The subtype
selectivity of these models was tested on the 21–408 known
subtype selective ligands and the 39–147 known multi-subtype
ligands not in the training datasets.
The performance of our new method, 2SBR-SVM, and the
method developed in our previous studies, Combi-SVM [18], in
screening large compound libraries was evaluated by 13.56 million
PubChem compounds [23], 168,016 MDL Drug Data Report
(MDDR) database compounds, and 657,736 ChEMBLdb com-
pounds [43] which represent general chemical libraries, patented
bioactive agents, and published bioactive compounds respectively.
The capability of 2SBR-SVM in identifying subtype selective
ligands of other receptors was further evaluated against estrogen
receptor (ER) ERa and ERb subtype ligands by using the same
training and testing procedures as those of the dopamine receptor
subtype ligands.
Methods
Datasets
D1, D2, D3 and D4 ligands and non-ligands were collected
from comprehensive search of literatures [38,41,44,45] and
ChEMBLdb database [43] by using combinations of keywords:
‘‘dopamine’’, ‘‘D1 receptor’’, ‘‘D2 receptor’’, ‘‘D3 receptor’’, ‘‘D4
receptor’’, ‘‘ligand’’, ‘‘binding’’, ‘‘binder’’, ‘‘subtype selective’’, and
‘‘selective ligand’’. As the ligands were collected from different
sources with their binding affinities measured under different
assays and conditions, some level of variations in binding affinities
is expected. Therefore, we tentatively selected compounds with
binding affinity Ki ,1 mM against a dopamine receptor as its
ligands, and those with binding affinity Ki .10 mM as non-
ligands. The 1 mMt o1 0mM binding affinity gap between ligands
and non-ligands was used for reducing the possible influence of
experimental binding affinity variations on the robustness of
developed VS models. Some of the dopamine receptor ligands
have been explicitly reported to be subtype selective or multi-
subtype ligands, which can be used for testing the subtype selective
capability of our developed VS models. Thus for subtypes with
$20 subtype selective or $20 multi-subtype ligands, the
corresponding ligands were used as independent testing datasets
(a cut-off of 20 ligands was used to ensure the testing to be
statistically meaningful).
We assembled 491 D1, 2202 D2, 1355 D3 and 1486 D4 ligands
published before 2010 and 59 D1, 135 D2, 76 D3 and 29 D4
ligands published since 2010 with unspecified selectivity toward
other subtypes, and 264 D1, 1577 D2, 631 D3 and 526 D4 non-
ligands published before 2010 and 25 D1, 65 D2, 28 D3 and 33
D4 non-ligands published since 2010 with unspecified selectivity
toward other subtypes. The collected pre-2010 ligands and non-
ligands for each receptor subtype were used as positive and
negative samples of the training dataset for developing VS models
for that subtype. The collected non-ligands are insufficient to cover
the vast non-ligand chemical space. Therefore, putative ligands for
each receptor subtype were generated from the representative
compounds of the compound families that contain no known
ligand of that subtype by using the method described in our earlier
studies [19]. A total of 65198 D1, 63687 D2, 62927 D3 and 63272
D4 putative non-ligands were generated and used in combination
with known non-ligands as the negative samples of the training
datasets. The collected post-2010 ligands and non-ligands were
used as independent testing datasets for evaluating the perfor-
mance of the developed VS models. These datasets are
summarized in Table 1.
The use of pre-2010 and post-2010 compounds as training and
testing datasets was intended to mimic the case of VS models being
developed in 2010 and subsequently tested a few years later
against newly discovered compounds. In view that such training
and testing datasets and their developed models may not be easily
reproduced and comparatively evaluated, we designed alternative
training and testing datasets by randomly separating all ligands
and non-ligands of a receptor subtype into approximately 10
compound-sets, with 9 compound-sets as a training dataset and
the remaining 1 as a testing dataset (these training and testing
datasets contain similar number of compounds as the correspond-
ing ones developed from pre-2010 and post-2010 compounds).
There are 10 sets of training and testing datasets for each subtype
with each of the 10 compound-sets used as a testing dataset once,
all of which were tested in this work. These alternative datasets are
summarized in Table S1.
Dopamine receptor subtype selective ligands have been
discovered and evaluated based on the criterion that each ligand
binds to a specific subtype with at least ,10 fold higher binding
affinity (Ki value) than that to another subtype [46]. Based on this
criterion, we collected 97, 21, and 29 D1 selective ligands with
.10 fold higher binding affinity over D2, D3 and D4 respectively,
43, 37 and 63 D2 selective ligands over D1, D3 and D4
respectively, 48, 99 and 85 D3 selective ligands over D1, D2 and
D4 respectively, and 27, 408 and 207 D4 selective ligands over
D1, D2 and D3 respectively (Table 2). These subtype selective
ligands were used as the positive samples to test subtype selectivity
of our developed VS models.
The binding subtypes of a number of multi-subtype dopamine
ligands have been explicitly reported [16,17]. These ligands and
their binding subtypes were selected based on the criterion that
they bind to each subtype with binding affinity Ki ,1 mM. We
collected 4 groups of dual-subtype ligands (147 D1–D2, 4 D1–D3,
8 D1–D4, and 100 D3-D4 ligands), 2 groups of triple-subtype
ligands (39 D1–D2–D3 and 2 D1–D2–D3 ligands), and 1 group of
quadruple-subtype ligands (60 D1–D2–D3–D4 ligands). Four of
these groups with .10 ligands were selected as negative samples to
test the ability of our developed VS models in predicting multi-
subtype ligands (and thus the ability in separating subtype-selective
and multi-subtype ligands) (Table 3). There are three other
groups with high numbers of multi-subtype ligands (569 D2–D3,
276 D2–D4 and 402 D2-D3-D4 ligands). Separation of these
groups of multi-subtype ligands from the training datasets would
significantly compromise the structural diversity of the training
datasets. Therefore, these three groups were not removed from the
Virtual Screening of Dopamine Receptor Ligands
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does not enhance their subtype-selective signal. Instead they act as
noise that tends to reduce the capability of the developed VS
models in separating subtype-selective and multi-subtype ligands.
ERa and ERb ligands were collected in the same manner as
that of dopamine receptor ligands using keyword combinations of
‘‘estrogen’’, ‘‘estrogen receptor’’, ‘‘ER’’, ‘‘ER alpha’’, ‘‘ER beta’’,
‘‘ligand’’, ‘‘binding’’, ‘‘binder’’, ‘‘subtype selective’’, and ‘‘selective
ligand’’. We collected 1146 ERa and 1234 ERb ligands (with
unknown status about their subtype selectivity or multi-subtype
binding) and 761 and 786 ERa and ERb non-ligands, which
together with 64013 and 60603 putative ERa and ERb non-
ligands (generated by the same procedure as the putative
dopamine receptor subtype non-ligands) were used for training
2BR-SVM VS models using the same procedure as that of the
alternative dataset version of dopamine receptor subtype selective
VS models. There are 10 sets of randomly assembled training and
testing datasets for each estrogen receptor subtype with each of the
10 randomly generated compound-sets used as a testing dataset
once, all of which were tested in this work. We also collected 40
and 55 ERa and ERb selective ligands (with binding affinity ratios
in the range of 10–2055 and 10–1143) and 63 ERa and ERb
multi-target ligands, which were used as independent testing
datasets for testing the VS models. These datasets are summarized
in Table S2.
Molecular representations
The 2D structures of our collected compounds were drawn by
using Chemdraw or from the ChEMBLdb [43] and Pubchem [23]
databases. Each compound was represented by 98 molecular
descriptors (Table S3) computed by using own developed
MODEL program [47]. These 98 descriptors have been selected
in our previous studies for developing VS models of a variety of
target classes including GPCR ligands to screen large chemical
libraries such as Pubchem compounds [18,19,48]. Although the
structures of the binders of one target or subtype can be very
different from those of another target or subtype, each binders set
plus the representatives of the non-binders cover the same
chemical space defined by the 13.56 million Pubchem com-
pounds. Therefore, the same set of molecular descriptors was used
in this work as well as our previous works [18,48].
Table 2. Datasets of our collected dopamine receptor D1, D2, D3 and D4 selective ligands against another subtype.
Dopamine receptor
subtype
Selectivity against
the second subtype
Number of subtype selective
ligands against the second
subtype
Range of binding
affinity ratio
Mean of binding
affinity ratio
D1 D2 97 10–4533 359
D3 21 11–559 122
D4 29 11–4600 770
D2 D1 43 10–3707 337
D3 37 10–615 66
D4 63 10–1851 113
D3 D1 48 17–38461 3863
D2 99 10–6666 259
D4 85 10–9111 950
D4 D1 27 13–4761 1315
D2 408 10–10752 2962
D3 207 10–51162 1175
The binding affinity ratio is the experimentally measured binding affinity to the second subtype divided by that to the first subtype: (Ki of the second subtype / Ki of the
first subtype). This dataset was used as positive samples for testing subtype selectivity of our developed virtual screening models.
doi:10.1371/journal.pone.0039076.t002
Table 3. Datasets of our collected dopamine receptor multi-subtype ligands.
Ligand Group Binding Subtypes
Number of Ligands of
Subtypes Used as Testing Dataset
Dual Subtype Ligands D1 and D2 147 Yes
D1 and D3 4 No
D1 and D4 8 No
D3 and D4 100 Yes
Triple Subtype Ligands D1, D2 and D3 39 Yes
D1, D3 and D4 2 No
Quadruple Subtype Ligands D1, D2, D3 and D4 60 Yes
Four groups of this dataset were used as negative samples for testing subtype selectivity of our developed multi-label machine learning models.
doi:10.1371/journal.pone.0039076.t003
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SVM is based on the structural risk minimization principle for
minimizing both training and generalization error [49]. In linearly
separable cases, SVM constructs a hyper-plane to separate active
and inactive classes of compounds with a maximum margin. In
nonlinearly separable cases, which frequently occur in classifying
compounds of diverse structures [18,19,48], SVM maps the input
vectors into a higher dimensional feature space by using the Radial
Basis Function (RBF) kernel function. This kernel function has
been extensively used and consistently shown better performance
than other kernel functions [50,51,52]. In the high dimensional
space, linear SVM can be applied for classifying the active and
inactive compounds. For the parameters, a hard margin
C=100000 was used and s=0.4–0.6 were determined from 5
fold cross validation studies.
Combinatorial SVM method
In combinatorial strategy, SVM models for each receptor
subtype are separately constructed, which are subsequently used
for parallel screening against each individual subtype to find
compounds that only bind to one of the subtypes (putative subtype
selective ligands) or simultaneously bind to multiple subtypes
(putative subtype non-selective ligands) [18,48].
Two-step Binary relevance SVM method
Subtype selective ligands were selected by two steps. In the first
step, a high performance SVM model was developed for each
receptor subtype to select ligands of that subtype regardless of their
selectivity towards other subtypes. The high performance in
selecting ligands of a subtype was achieved by using comprehen-
sive sets of known ligands and putative non-ligands of the
corresponding receptor to train the respective SVM model [19].
In the second step, the Binary relevance (BR) method [30] was
used for more refined selection of subtype selective ligands from
the putative ligands selected in the first step. BR is a popular
multiple binary classification method that transforms the original
N-label dataset into N pairs of datasets with samples of each label
as positive dataset and samples of the other N-1 labels as negative
dataset [30].
Multi-label K nearest neighbor method
ML-kNN implemented in the Mulan software package [30] was
used in this work. ML-kNN [31] extends traditional kNN method
to solve the multi-label problem. In the first step, ML-kNN
classifies a compound x by linking it to the known ligand or non-
ligand xi in the training dataset with closest Euclidean distance
[53]. In the second step, statistical information, i.e. prior and
posterior probabilities for the frequency of each label within the k
nearest neighbors, is gained from the label sets of these
neighboring ligands. In the third step, maximum a posteriori
(MAP) principle is used to determine the label set for the unknown
ligands. The default parameters in Mulan package were used in
this work.
The random k-labelsets decision tree method
RAkEL-DT implemented in the Mulan software package [30]
was used in this work. The random k-labelsets (RAkEL) method
[32] constructs an ensemble of label powerset (LP) classifiers. LP is
a transformation method which considers each unique set of labels
existed in multi-label training set as new single label. Since RAkEL
is a transformation-based algorithm and it accepts a single-label
classifier as a parameter, decision tree C4.5 algorithm was used for
this purpose. C4.5 decision tree is a branch-test-based classifier
[54]. A branch in a decision tree corresponds to a group of classes
and a leaf represents a specific class. A decision node specifies a
test to be conducted on a single attribute value, with one branch
and its subsequent classes as possible outcomes of the test. C4.5
decision tree uses recursive partitioning to examine every attribute
of the data and to subsequently rank them according to their
ability to partition the remaining data, thereby constructing a
decision tree. The default parameters in Mulan package were used
in this work.
Virtual screening model development, parameter
determination and performance evaluation
All VS models for each dopamine receptor subtype were trained
from the training datasets in Table 1. The parameters were
determined by 5-fold cross validation (CV) tests, and the
performance of these VS models was evaluated by using the
independent testing datasets in Table 1. In each 5-fold CV test,
the training dataset was divided into 5 groups of approximately
equal number of positive samples and equal number of negative
samples, with 4 groups used for training and 1 group used for
testing the model. There are five such sets each with one unique
group used as a testing set, from which five prediction models can
be constructed. VS models were developed at different parame-
ters. The parameters with the best overall 5-fold CV performance
were selected for developing the final VS models.
The performance indicators can be derived from the numbers
of true positives TP (true inhibitors), true negatives TN (true non-
inhibitors), false positives FP (false inhibitors), and false negatives
FN (false non-inhibitors). In 5-fold cross validation studies, the
inhibitor and non-inhibitor prediction accuracies are given by
sensitivity SE=TP/(TP+FN)*100 and specificity SP=TN/
(TN+FP)*100 respectively. Prediction accuracies have also been
frequently measured by overall prediction accuracy (Q) and
Matthews correlation coefficient (C) [55].
Q~
TPzTN
TPzTNzFPzFN
ð1Þ
C~
TP   TN{FN   FP
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(TPzFN)(TPzFP)(TNzFN)(TNzFP)
p ð2Þ
In the large database screening tests, the yield and false-hit rate
are given by TP/(TP+FN) and FP/(TP+FP) respectively.
Determination of similarity level of a compound against
dopamine receptor ligands in a dataset
The similarity level of a compound i with respect to the ligands
of a dataset can be determined by using the Tanimoto coefficient
sim(i,j): [56].
sim(i,j)~
P l
d~1
xdi xdj
P l
d~1
(xdi )
2z
P l
d~1
(xdj )
2{
P l
d~1
xdi xdj
ð3Þ
where xdi represents a molecular fingerprint of compound i
(there are 882 fingerprints calculated from the PaDEL-Descriptors
program [57], l is the number of molecular fingerprints, j is the
index of the ligand in the dataset most similar to compound i. The
compound i. is assigned into one of the ten similarity levels based
Virtual Screening of Dopamine Receptor Ligands
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0.5–0.6, 0.4–0.5, 0.3–0.4, 0.2–0.3, 0.1–0.2, and 0–0.1. Com-
pounds are typically considered to be highly similar if sim(i,j) is no
less than 0.8 or 0.9 [58,59].
Determination of dopamine receptor subtype selective
features by feature selection method
Molecular features important for dopamine receptor subtype
selective ligands were probed by using a feature selection method,
recursive feature elimination (RFE) method, extensively used in
selecting molecular features of compounds of specific pharmaco-
dynamic and pharmacokinetic properties 60]. In this approach,
the level of contribution of individual molecular descriptor to
SVM classification of ligands of a subtype against ligands of other
subtypes was ranked and the top-ranked ones were selected based
on the evaluation of the variation of the SVM objective function J
caused by the removal of an individual descriptor 61]. The
variation DJ(i) due to the removal of a descriptor i is computed by
DJ(i)~
1
2
L
2J
Lw2
i
(Dwi)
2 with the weight variation determined by
Dwi = wi. In this work, Gaussian kernels were used for developing
SVM models. In this case, DJ(i)~(1=2)aTHa{(1=2)aTH({i)a,
where H is the matrix with elements y i y j exp(-||xi - xj||
2/(2s
2)),
H(-i) is the matrix computed by the same method as matrix H but
with its i-th component removed, y i is the vector composed of
molecular descriptors, 1 is an m dimensional identity vector (m is
the number of compounds in a training dataset), and the
component of vector a is kept in the range of 0 # a k # C.
The computational procedure for selecting subtype selective
features is as follows: For a specific subtype, the corresponding
SVM model developed in the second step of the 2SBR-SVM
method is processed by iteratively evaluating and eliminating
molecular descriptors at different parameter s values based on 5-
fold cross-validation. In the first step, for a fixed s, the SVM is
trained by using the complete set of descriptors (feature set). The
second step is to compute the ranking criterion score DJ(i) for
every existing descriptor. All the computed DJ(i) is then ranked in
descending order. The third step is to remove the m descriptors
with smallest criterion scores (m=4 in this work). In the fourth
step, the SVM is retrained by using the remaining molecular
descriptors and a new prediction accuracy of 5-fold cross-
validation is computed. The second to fourth steps are repeated
for multiple-iterations until all descriptors are removed. For
another fixed s, the first to fourth steps are repeated.
Results and Discussion
5-fold cross-validation tests
The results of 5-fold CV tests of the SVM models of D1, D2, D3
and D4 ligands are shown in Table S4. Overall, the sensitivity,
specificity, overall accuracy and the Matthews correlation
coefficients of the best performing SVM models are in the range
of 87.8%–95.3%, 99.6%–99.9%, 99.3%–99.8%, and 0.74–0.90
respectively. These results are comparable to those of our earlier
studies [48], indicating that the SVM models for dopamine
receptor subtypes have similar prediction capability as those for
other target classes. The VS models with the best 5–fold CV
performance were further tested on independent sets of dopamine
receptor ligands and non-ligands published since 2010 and not in
the training datasets, which are also shown in Table S4. The
sensitivity, specificity and overall accuracy are in the range of
71.2%–89.7%, 61.5%–76.0% and 71.4%–82.7% respectively.
The sensitivity is substantially smaller than that of 5–fold CV
tests. This is because many of the post–2010 ligands in the
independent datasets are structurally different from those of the
pre-2010 ligands in the training datasets. As shown in Table 1,
16.3%–34.5% of the post–2010 ligands are outside the chemical
families of pre-2010 ligands in the training datasets. The specificity
is also significantly smaller than that of the 5-fold CV tests. This is
partly because many non-ligands have weak (Ki 10–50 mM)
binding activity and may thus be difficult to be separated from the
ligands.
The VS performance of the SVM VS models developed by the
10 sets of alternative training and testing datasets is provided in
Table S1. The sensitivity, specificity, overall accuracy and the
Matthews correlation coefficients of these SVM models in
classifying dopamine receptor subtype ligands and non-ligands
are in the range of 79.1%–94.8%, 99.6%–99.9%, 99.3%–99.9%,
and 0.73–0.90 respectively, which are very similar to those of the
SVM models developed by pre–2010 and tested by post-2010
compounds. A further analysis of structures of the randomly
assembled datasets and those of the chronologically assembled
datasets showed that most of the active and inactive scaffolds are
mutually represented on both sides because of the significant
structural diversity in these datasets. Therefore, the VS perfor-
mance of SVM models developed by chronologically assembled
datasets can be compared with those models developed by using
datasets assembled by conventional approach.
Applicability domains of the developed SVM VS models
Our SVM VS models for each dopamine receptor subtype were
developed by using known ligands and non-ligands of the subtype,
and the putative non-ligands composed of representative com-
pounds of all of the compound families in the Pubchem chemical
space that contain no known ligand of the subtype. Theoretically,
these VS models are expected to be applicable in the chemical
space defined by the known ligands, known non-ligands, and the
13.56 M Pubchem compounds. If this is true, in addition to good
predictive performance on the known ligands, these VS models are
expected to consistently identify very small percentages of
Pubchem compounds as subtype selective ligands regardless of
their similarity levels to the known ligands. Alternatively, if the
applicability domain of these models covers limited chemical space
around known ligands, then the number of identified Pubchem
compounds may increase substantially beyond the applicability
domain (i.e. at lower similarity levels). To determine the
applicability domain of each SVM VS model, we divided
13.56 M PubChem compounds into groups of 10 similarity levels
with respect the known ligands of each receptor subtype (defined
in the methods section), and then monitored if the number of the
SVM identified PubChem compounds significantly increases at
higher similarity levels. As shown in Table S5, the percentages of
identified Pubchem compounds for all four receptor subtypes
(0.0489%–0.0521% for D1, 0.131%–0.135% for D2, 0.143%–
0.147% for D3, and 0.157%–0.160% for D4 respectively) are
consistently small and show little variations at different similarity
levels. This suggests that the applicability domains of our SVM VS
models likely cover the chemical space defined by the known
ligands, known non-ligands and the PubChem compounds.
Prediction performance on dopamine receptor subtype
selective and multi-subtype ligands
The performance of our new method 2SBR-SVM and that of
the three previously used methods Combi-SVM, ML-kNN and
RAkEL-DT in predicting dopamine subtype selective ligands was
determined as follows: For each set of dopamine receptor subtype
selective ligands against another subtype, the developed VS model
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screen these ligands. The percentage of these ligands selected by
the first model but not by the second model was used to measure
the performance of the VS models in selecting subtype selective
ligands. The relevant results are shown in Table 4.
As shown in Table 4, the three previously used methods
showed mostly moderate and in minority cases good performance
in predicting dopamine receptor subtype selective ligands.
Specifically, 13.4%–23.8%, 14.3%–55.8%, 17.7%–77.9% and
26.8%–74.1% of the D1, D2, D3 and D4 selective ligands were
correctly predicted by Combi-SVM as subtype selective ones. ML-
kNN showed better performance, correctly predicting 23.8%–
58.6%, 21.6%–62.8%, 26.3%–87.5% and 24.4%–70.4% of the
D1, D2, D3 and D4 selective ligands as subtype selective ones. The
RAkEL–DT method achieved the best performance among the
three methods, correctly predicting 44.8%–75.3%, 30.2%–69.8%,
22.4%–85.4% and 45.5%–85.2% of the D1, D2, D3 and D4
selective ligands as subtype selective ones. On the other hand, our
new method 2BR–SVM produced significantly improved perfor-
mance, correctly predicting 66.5%–86.6%, 81.1%–93.0%,
50.6%–56.3% and 82.5%–88.0% of the D1, D2, D3 and D4
selective ligands as subtype selective ones. This suggests that our
two–step strategy with one step focusing on subtype binding and
another on selectivity works more effectively than the three
previously used methods in predicting dopamine receptor subtype
selective ligands.
The improved subtype selective performance of the 2BR-SVM
method arises from its more rigorous evaluation of minor
structural and physicochemical differences of subtype selective
ligands. Comparative structural analysis has shown that some D2
selective and D3 selective ligands are highly similar in structure
and interact with their respective subtypes in a very similar binding
mode with some functional group adopting different orientation at
sites of non-conserved residues [46]. Such minor differences may
not be adequately distinguished by conventional VS models
developed by training datasets with inadequate representation of
ligands of other subtypes, but may be distinguished by 2BR-SVM
method with additional models developed by training datasets
with sufficient representation of other subtypes.
The performance in predicting dopamine subtype selective
ligands is measured not only by the capability in selecting subtype
selective ligands, but also on the ability in differentiating them
from multi-subtype ligands. Good prediction on subtype selective
ligands needs to be complemented by equally good performance in
predicting multi-subtype ligands as subtype non-selective ones.
This performance was determined as follows: For each set of
multi-subtype ligands (e.g. triple-subtype D1, D2 and D3 ligands),
the VS models of all of the corresponding subtypes (e.g. D1, D2
and D3) were used to screen the multi-subtype ligands in the set.
The percentage of these ligands selected by the model of more
than one subtype was used to measure the performance of the VS
models in predicting multi-subtype ligands as subtype non-
selective ligands. The results are shown in Table 5.
Of the three previously used methods, Combi-SVM showed the
best performance in predicting dopamine receptor multi-subtype
ligands as subtype non-selective ones, correctly predicting 68.0%,
83.0%, 76.9% and 75.4% of the D1-D2, D3-D4, D1-D2-D3 and
D1-D2-D3-D4 multi-subtype ligands as subtype non-selective
ones. On the other hand, only 32.0%, 37.0%, 28.2% and 36.7%
of the D1-D2, D3-D4, D1-D2-D3 and D1-D2-D3-D4 multi-
subtype ligands were predicted by ML-kNN as subtype non-
selective ones, and only 35.4%, 39.0%, 33.3% and 38.8% of the
D1-D2, D3-D4, D1-D2-D3 and D1-D2-D3-D4 multi-subtype
ligands were predicted by RAkEL-DT as subtype non-selective
ones. Hence, the better performance of ML-kNN and RAkEL-DT
over Combi-SVM in predicting subtype selective ligands is off-set
Table 4. The performance of our new method 2SBR-SVM and that of previously used methods Combi-SVM, ML-kNN and RAkEL-DT
in predicting dopamine receptor subtype selective ligands.
Percent of subtype selective ligands predicted as subtype
selective with respect to the second subtype
Dopamine receptor
subtype
Selectivity against the
second
subtype
Number of
subtype
selective ligands Combi-SVM ML-kNN RAkEL-DT 2SBR-SVM
D1 D2 97 13.40% 30.93% 75.26% 86.60%
D3 21 23.81% 23.81% 47.62% 66.67%
D4 29 17.24% 58.62% 44.83% 65.52%
average 18.15% 37.79% 55.90% 72.93%
D2 D1 43 55.81% 62.79% 69.77% 93.02%
D3 37 16.22% 21.62% 62.16% 81.08%
D4 63 14.29% 39.68% 30.16% 82.54%
average 28.77% 41.36% 54.03% 85.55%
D3 D1 48 72.92% 87.50% 85.42% 56.25%
D2 99 22.22% 26.26% 50.51% 51.52%
D4 85 17.65% 31.76% 22.35% 50.59%
average 37.60% 48.51% 52.76% 52.79%
D4 D1 27 74.07% 70.37% 85.19% 82.50%
D2 408 33.33% 28.43% 57.60% 88.00%
D3 209 26.79% 24.40% 45.46% 83.73%
average 44.73% 41.07% 62.75% 84.74%
doi:10.1371/journal.pone.0039076.t004
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subtype non-selective. Taken these two indicators together,
Combi-SVM appears to show better overall performance in
predicting subtype selective and subtype non-selective ligands than
the ML-kNN and RakEL-DT methods.
The performance of our new method 2SBR-SVM in predicting
dopamine receptor subtype non-selective ligands is similar to that
of Combi-SVM, correctly predicting 76.2%, 81.0%, 71.8% and
71.7% of the D1-D2, D3-D4, D1-D2-D3 and D1-D2-D3-D4
multi-subtype ligands as subtype non-selective ones. Thus, our new
method maintains the same performance level as that of the best
performing method of the previously used methods in predicting
dopamine receptor subtype non-selective ligands. The lack of
improvement by our new method in predicting dopamine receptor
subtype non-selective ligands may be partly due to the quality of
training datasets. It is noted that three groups of multi-subtype
ligands were included as positive samples in the training datasets,
which likely affect the ability of the SVM models in predicting
multi-subtype ligands as subtype non-selective ones.
Virtual screening performance in searching large
chemical libraries
The virtual screening performance of our new method 2SBR-
SVM and our previously developed method Combi-SVM was
evaluated by using them to screen 13.56 M Pubchem compounds,
168,016 MDDR compounds and 657,736 ChEMBLdb com-
pounds to determine the numbers of Pubchem, MDDR, and
ChEMBLdb compounds predicted as D1, D2, D3 and D4
selective ligands, which are shown in Table 6. For comparison,
Table 6 also includes the results of SVM (single label) in
identifying Pubchem compounds as putative D1, D2, D3 and D4
ligands regardless of their possible binding with another subtype.
In screening Pubchem compounds, the number of D1, D2, D3
and D4 selective virtual hits identified by 2SBR-SVM and the
corresponding virtual hit rate is 650 and 0.0048%, 1132 and
0.0083%, 1498 and 0.011%, and 1961 and 0.015% respectively,
which is significantly smaller than those identified by Combi-
SVM. The number of D1, D2, D3 and D4 selective virtual hits
identified by Combi-SVM and the corresponding virtual hit rate is
4948 and 0.037%, 10080 and 0.074%, 6055 and 0.045%, and
9180 and 0.068% respectively. The number of virtual hits
identified by Combi-SVM is nonetheless substantially smaller
than that of single label SVM. The number of D1, D2, D3 and D4
selective virtual hits identified by single label SVM and the
corresponding virtual hit rate is 6798 and 0.05%, 17786 and
0.13%, 19813 and 0.15%, and 21444 and 0.16% respectively.
Some of the identified virtual hits are possible subtype selective
ligands. Therefore the true false hit rates of the tested VS models
are likely smaller than the computed virtual hit rates. The false hit
rates of 2SBR-SVM in screening 13.56 million Pubchem com-
pounds can then be estimated as #0.0048%, #0.0083%,
#0.011% and #0.015% for D1, D2, D3 and D4 selective ligands
respectively. Therefore, 2SBR-SVM produced very low false hit
rates in screening large chemical libraries as well as good
performance in selecting subtype selective ligands.
As shown in Table 6, in screening MDDR and ChEMBLdb
compounds, 2SBR-SVM as well as Combi-SVM and single label
SVM produced reasonably low virtual hit rates that are in the
range of 0.06%–0.09% and 0.05%–0.14% respectively, which are
10 fold higher than those in screening Pubchem compounds.
MDDR and ChEMBLdb compounds as a collection of bioactive
agents tend to be structurally closer to the dopamine receptor
ligands than many Pubchem compounds that consist of high
percentage of inactive compounds. Therefore, it tends to be more
difficult for 2SBR-SVM to distinguish dopamine receptor ligands
from some of the non-ligands in MDDR and ChEMBLdb
databases, leading to higher virtual-hit rates. The virtual hit rates
of 2SBR-SVM in screening MDDR and ChEMBLdb compounds
are substantially (2–10 fold) smaller than those of Combi-SVM
and single label SVM, which suggests that 2SBR-SVM is capable
of achieving lower false-hit rate in screening bioactive compounds
than more conventional SVM methods.
Although it is unclear how many true D1, D2, D3 and D4
selective ligands are contained in Pubchem database. Some crude
estimates can be made. As shown in Table 1 and Table 2, the
number of known ligands of a dopamine receptor subtype is in the
range of 550–2337, and the number of known dopamine receptor
subtype selective ligands is in the range of 21–408. The known
subtype selective ligands are approximately 10 fold less in numbers
than the known ligands of a subtype. While the numbers of the
published D1, D2, D3, and D4 ligands continuously increase
through the years (Figure S1, S2, S3 and S4), there are signs of
significant reduction of the growth rates at the level of 2000–3000
ligands. These trends tend to project the existence of no more than
several thousand undiscovered ligands for each dopamine receptor
subtype in the chemical space defined by the Pubchem, MDDR
and ChEMBLdb compounds. Hence, the number of subtype
selective virtual hits identified by 2SRB-SVM is closer to the
estimated upper limit of undiscovered dopamine receptor subtype
ligands than those of Combi-SVM and single label SVM.
Table 5. The performance of our new method 2SBR-SVM and that of previously used methods Combi-SVM, ML-kNN and RAkEL-DT
in predicting dopamine receptor multi-subtype ligands as non-selective ligands.
Percent of multi-subtype ligands predicted as non-selective
ligands
Ligand
Group
Binding
subtypes
Number of Multi-
Subtype
Ligands Combi-SVM ML-kNN RAkEL-DT 2SBR-SVM
Dual Subtype Ligands D1 and D2 147 68.02% 31.97% 35.37% 76.19%
D3 and D4 100 83.0% 37.0% 39.0% 81.0%
Triple Subtype Ligands D1, D2 and D3 39 76.92% 28.2% 33.33% 71.79%
Quadruple Subtype
Ligands
D1, D2, D3 and D4 60 75.42% 36.67% 38.75% 71.67%
doi:10.1371/journal.pone.0039076.t005
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The molecular descriptors important for distinguishing the
ligands of every dopamine receptor subtype and the ligands of
other subtypes were determined by using the feature selection
method [60] outlined in the method section, which are provided in
Table 7. The top-ranked D1 selective descriptors are number of
O atoms, sum of Estate of atom type dssC, ssO and ssNH, graph-
theoretical shape coefficient, and sum of H Estate of atom type
HsNH2. These descriptors are consistent with the D1 selective
features derived from a pharmacophoric model that includes
positive nitrogens (linked to ssNH, HsNH2), hydrogen bond
acceptor (linked to O, ssO) and donor (linked to ssNH, HsNH2)
[14]. The top-ranked D2 selective descriptors are number of H-
bond acceptor, sum of H Estate of atom types HaaNH and
HCsats, and sum of Estate of atom type dssC, aasC and aaNH.
These are consistent with a CoMSIA based analysis that suggests
that D2 selectivity is determined by hydrogen bond acceptor
(linked to H-bond acceptor) and donor (linked to HaaNH),
hydrophobic (linked to HCsats, dssC, aasC), and electrostatic
(linked to HaaNH, aaNH) factors [10]. These are also consistent
with the conclusion from a pharmacophoric model that two
hydrogen acceptors or one hydrogen acceptor plus one donor are
critically important for D2 selectivity of some ligands [14].
The top-ranked D3 selective descriptors are sum of Estate of
atom type dsCH, aaaC and sOH, sum of H Estate of atom type
HsOH and HCsats, and number of H-bond donor. These are
consistent with the conclusions from several CoMSIA models that
correlate D3 selectivity with specific hydrogen bond donor (linked
to H-bond donor, sOH, HsOH), hydrophobic (linked to dsCH,
aaaC), and electrostatic (linked to sOH, HsOH) factors [10,15].
Moreover, a study of a D3 selective ligand further shows that
hydrogen bonding from a hydroxyl group is important for
conferring D3 selectivity [10]. The top-ranked D4 selective
descriptors are molecular path count of length 2, sum of Estate
of atom type ssCH2 and aasC, 3th order Kier shape index,
topological radius, and Kier molecular flexibility index. These are
consistent with a report that D4 selectivity is strongly influenced by
the geometry and orientation of specific chemical groups (linked to
molecular path count of length 2, 3th order Kier shape index,
topological radius, and Kier molecular flexibility index) [9]. The
consistency of our selected molecular descriptors and the
literature-reported features for D1, D2, D3, and D4 selectivity
suggests that the subtype selective molecular descriptors selected
by our feature selection method may be potentially useful for
facilitating the design or search of dopamine subtype selective
ligands.
Virtual screening performance of the two-step binary
relevance SVM method in searching estrogen receptor
subtype selective ligands
The VS performance of the SVM models for each ER subtype
developed by the 10 sets of randomly assembled training and
testing datasets is provided in Table S2. The sensitivity,
specificity, overall accuracy and the Matthews correlation
coefficients of these SVM models in classifying ER subtype ligands
and non-ligands are in the range of 92.9%–97.6%, 99.7%–99.9%,
99.7%–99.9%, and 0.84–0.92 respectively, which are very similar
to those of the dopamine receptor subtype. Moreover, as shown in
Table S6 and S7, the performance of 2SBR-SVM in identifying
ERa selective ligands (85.0%), ERb selective ligands (80.0%), ERa
and ERb multi-subtype ligands (69.8%), and in screening
Pubchem, MDDR and ChEMBLdb compounds (virtual hit rates
0.0094%–0.0104%, 0.056%–0.064%, and 0.033%–0.034%) is at
very similar levels as those of the dopamine receptor subtype.
Therefore, our 2BR-SVM method is likely applicable to different
receptor-ligand systems.
Table 6. Virtual screening performance of our new method 2SBR-SVM and that of our previously used method Combi-SVM in
scanning 168,016 MDDR compounds and 657,736 ChEMBLdb compounds, and 13.56 million Pubchem compounds.
Dopamine
receptor
subtype Method
Number and Percent of the
13.56M
PubChem Compounds
Identified as subtype
selective ligands
Number and Percent of the
168,016 MDDR
Compounds Identified as
subtype selective ligands
Number and Percent of the
657,736
ChemBLdb Compounds
Identified as subtype selective
ligands
D1 SVM
(Single Label)
6798(0.0501%) 463(0.28%) 1034(0.16%)
Combi-SVM 4948(0.0365%) 383(0.23%) 755(0.11%)
2SBR-SVM 650(0.0048%) 140(0.08%) 355(0.05%)
D2 SVM
(Single Label)
17786(0.1312%) 1105(0.66%) 3208(0.49%)
Combi-SVM 10080(0.0743%) 712(0.42%) 2023(0.31%)
2SBR-SVM 1132(0.0083%) 108(0.06%) 686(0.10%)
D3 SVM
(Single Label)
19813(0.1461%) 1149(0.68%) 3057(0.46%)
Combi-SVM 6055(0.0447%) 679(0.40%) 1894(0.29%)
2SBR-SVM 1498(0.0110%) 156(0.09%) 687(0.10%)
D4 SVM
(Single Label)
21444(0.1581%) 1160(0.69%) 3489(0.53%)
Combi-SVM 9186(0.0677%) 790(0.47%) 2579(0.39%)
2SBR-SVM 1961(0.0145%) 134(0.08%) 907(0.14%)
For comparison, the results of single label SVM, which identify putative subtype binding ligands regardless of their possible binding to another subtype, are also
included.
doi:10.1371/journal.pone.0039076.t006
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Virtual screening methods have been increasingly explored for
facilitating the discovery of target selective drugs for enhanced
therapeutics and reduced side effects. Our study further suggested
that the two-step target binding and selectivity support vector
machines virtual screening tools developed from protein subtype
ligands with unspecified subtype selectivity are capable of
identifying protein subtype selective ligands at good yields, subtype
selectivity and low false-hit rates in screening large chemical
libraries. Our method may be combined with other virtual
screening methods [62,63,64,65,66,67,68] to facilitate more
effective and efficient search of novel subtype selective drug leads
from larger chemical libraries. The capability of virtual screening
tools can be further enhanced by the incorporation of the
knowledge of existing and newly discovered subtype selective [2,4]
and multi-subtype [16,17] ligands, and by the further improve-
ment of virtual screening algorithms and parameters
[19,69,70,71,72,73,74].
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Table 7. Top-ranked molecular descriptors for distinguishing dopamine receptor subtype D1, D2, D3 or D4 selective ligands
selected by RFE feature selection method.
Dopamine
receptor
subtype
Top-ranked molecular descriptors for distinguishing subtype selective ligands and ligands of
other subtypes
D1 Number of O atoms, Sum of Estate of atom type dssC, Sum of Estate of atom type ssO, Sum of Estate of atom
type ssNH, Graph-theoretical shape coefficient, Sum of H Estate of atom type HsNH2
D2 Number of H-bond acceptor, Sum of H Estate of atom type HaaNH, Sum of H Estate of atom type HCsats, Sum of
Estate of atom type dssC, Sum of Estate of atom type aasC, Sum of Estate of atom type aaNH
D3 Sum of Estate of atom type dsCH, Sum of H Estate of atom type HsOH, Sum of H Estate of atom type HCsats,
Sum of Estate of atom type aaaC, Sum of Estate of atom type sOH, Number of H-bond donnor
D4 Molecular path count of length 2, Sum of Estate of atom type ssCH2, 3th order Kier shape index, Topological
radius, Sum of Estate of atom type aasC, Kier Molecular Flexibility Index
doi:10.1371/journal.pone.0039076.t007
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